DocGo (DCGO) Q1 2026 Earnings Transcript

DocGo reported Q1 revenue of $75.6 million, with the year-over-year decline driven entirely by the wind-down of migrant-related projects, while core revenue ex-migrant projects rose 24%. Management raised full-year 2026 revenue guidance to $300 million-$315 million from $290 million-$310 million, led by SteadyMD's $9.5 million quarter and strong growth in medical transportation and mobile health, though adjusted EBITDA loss guidance stayed at $5 million-$10 million. Margin pressure from higher fuel costs, clinician incentives, and hiring inefficiencies kept adjusted EBITDA at a $10.2 million loss and offset the revenue upside.

Analysis

The market should treat this as a transition quarter, not a clean fundamental inflection. The headline revenue reset is mechanically improving quality of revenue, but the operating model is still in a digestion phase: DCGO is replacing low-duration, policy-sensitive revenue with higher-quality recurring healthcare and transport volumes, yet it is doing so while carrying incremental labor friction and fuel exposure. That means the near-term equity tape can improve on top-line optics while cash conversion and EBITDA lag for another 1-2 quarters.

The most important second-order effect is mix. SteadyMD is not just an add-on; it is becoming the control layer that can increase utilization across the rest of the platform, especially in-home visits and monitoring. If management actually stitches virtual triage to field execution, the company can squeeze more revenue per patient and raise switching costs with payers and pharmacy partners. The flip side is that this same integration temporarily inflates cost-to-serve because staffing gaps, training, and incentive pay hit before routing efficiency and cross-sell benefits show up.

The bigger risk is that investors underweight working-capital strain because the business is growing into inventory-like labor and receivables needs. If fuel stays elevated and collections remain lumpy, the company can look operationally better than it feels financially, which keeps dilution or balance-sheet optionality on the table if the strategic review drags. In that setup, the stock likely trades more on guidance credibility and M&A probability than on current-period EBITDA.

Consensus may be too focused on the revenue raise and not enough on the durability of margin expansion. The real catalyst is not one quarter of growth; it is whether Q3 shows sequential SG&A compression and fewer temporary margin leaks. If that happens, the market can re-rate the business as a scaled healthcare services platform rather than a post-migrant cleanup story; if not, the current optimism fades quickly once the guidance bridge stops getting credit.

Key Decisions for Investors

• Long DCGO on 6-12 month horizon, but only on pullbacks after the print; risk/reward improves if the market gives back the guidance bump before Q3 evidence on SG&A and margin recovery.
• Buy DCGO Jan-2027 call spreads to express upside from a strategic transaction or re-rating, while limiting downside if working-capital pressure or fuel costs keep EBITDA stuck; best if implied vol stays moderate.
• Pair trade: long DCGO / short a lower-growth healthcare staffing or transport peer with weaker volume momentum; thesis is DCGO’s mix shift and utilization leverage should outperform once temporary cost headwinds ease.
• Do not add aggressively until Q3 commentary confirms sequential SG&A decline and stable cash conversion; that is the earliest point where the market can underwrite a cleaner free-cash-flow path.
• If DCGO rallies hard on M&A speculation alone, fade strength with a short-dated call spread overwrite rather than outright shorting; the strategic review creates upside tails, but the near-term operating bridge still caps conviction.